Pliant Therapeutics (Nasdaq: PLRX) today announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with ...
Aicuris’s pritelivir is forecast to be a significant advancement for immunocompromised patients with refractory HSV ...
A prespecified interim analysis showed statistically significant PFS improvement with elranatamab versus ...
Single agent duvelisib demonstrated clinically meaningful response rates, including a substantial proportion of complete responses, in a heavily ...
Stereotactic arrhythmia radioablation reduces sustained ventricular tachycardia episodes and defibrillator shocks in patients with treatment-refractory disease, without treatment related deaths.
Eptinezumab is associated with modest reductions in headache frequency for patients with chronic migraine with inadequate ...
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 dual-targeted immunotherapy combination regimen to be approved in ...
Epcoritamab monotherapy achieved high overall (84.6%) and complete response rates (67.1%) in relapsed/refractory follicular lymphoma patients with multiple prior therapies. Combination therapy with ...
Germ cell tumor (GCT) is one of the most common malignancies affecting young men. Approximately 30% of patients with metastatic disease experience disease progression following adequate first-line ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results